Announced details
Early Alzheimer's disease (slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer's disease)
Administration time is approximately 15 seconds per pen. The incidence of systemic reactions associated with injection is 1.4%.
Eisai and Biogen have partnered on the joint development and co-commercialization of Alzheimer's disease treatments since 2014. For lecanemab, Eisai leads global development and regulatory filings, and the companies jointly commercialize and co-promote the product under Eisai's final decision-making authority.
A biotechnology company headquartered in Cambridge, Massachusetts, USA. Its CEO is Christopher A. Viehbacher. Founded in 1978.
¥27,141 per pen
The impact on the forecast for the fiscal year ending March 2027 is expected to be immaterial, and there is no change to the earnings forecast announced on 15 May 2026.
The company does not address Contract Value.
Integrated results from the subcutaneous administration substudy of the Clarity AD trial and its long-term extension (LTE), modeling and simulation.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Leqembi Subcutaneous Injection 250 mg Pen, Leqembi (lecanemab) |
| Counterparty | Biogen Inc. (Nasdaq: BIIB) |
| Counterparty overview | A biotechnology company headquartered in Cambridge, Massachusetts, USA. Its CEO is Christopher A. Viehbacher. Founded in 1978. |
| Relationship with the Company | Eisai and Biogen have partnered on the joint development and co-commercialization of Alzheimer's disease treatments since 2014. For lecanemab, Eisai leads global development and regulatory filings, and the companies jointly commercialize and co-promote the product under Eisai's final decision-making authority. |
| Offering price | ¥27,141 per pen |
| Contract Date | 2014 (partnership for the joint development and commercialization of Alzheimer's disease treatments) |
| Launch date | 13 November 2026 (new launch, actual) |
| Applicable area | Early Alzheimer's disease (slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer's disease) |
| Quantitative Effects | Administration time is approximately 15 seconds per pen. The incidence of systemic reactions associated with injection is 1.4%. |
| Impact on Business Performance | The impact on the forecast for the fiscal year ending March 2027 is expected to be immaterial, and there is no change to the earnings forecast announced on 15 May 2026. |
| Source | Integrated results from the subcutaneous administration substudy of the Clarity AD trial and its long-term extension (LTE), modeling and simulation. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Self-administration shortens administration time and enables dosing at home or while away, reducing the burden of hospital visits and restrictions on going out and traveling, and improving the convenience and flexibility of treatment. The company explains that this also reduces the need for infusion capacity and healthcare resources such as nurse monitoring.